SCHEMBL6573336

SCHEMBL6573336

CCCS(=O)(=O)NC1CCCC1c1ccc(N(CC#N)Cc2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 11/20 0.41
GRIA2 P42262 1/20 0.35
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
PGGT1B P53609 1/20 0.33
SLC6A4 P31645 1/20 0.33
KDM1A O60341 2/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
CNR2 P34972 2/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
OPRK1 P41145 1/20 0.32
UTS2R Q9UKP6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6575437 0.86 GRIA4 (0.42) GRIA4GRIA2PSEN1PSEN2APH1B
SCHEMBL6573334 0.86 GRIA4 (0.60) GRIA4GRIA2
SCHEMBL6573331 0.86 GRIA4 (0.60) GRIA4GRIA2
SCHEMBL6573321 0.86 GRIA4 (0.42) GRIA4GRIA2PSEN1PSEN2APH1B
SCHEMBL6573845 0.85 GRIA4 (0.41) GRIA4GRIA2PSEN1PSEN2APH1B
SCHEMBL6762192 0.83 GRIA4 (0.40) GRIA4GRIA2PSEN1PSEN2APH1B
SCHEMBL6573066 0.79 GRIA4 (0.62) GRIA4GRIA2PSEN1PSEN2APH1B
SCHEMBL6574456 0.76 GRIA4 (0.47) GRIA4GRIA2PSEN1PSEN2APH1B
SCHEMBL6573755 0.72 GRIA4 (0.48) GRIA4GRIA2PSEN1PSEN2APH1B
SCHEMBL6573312 0.71 GRIA4 (0.61) GRIA4GRIA2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147612-A1 Sulfonamide derivatives DAVISON JOSHUA ZWICK (US) 2004-07-29 US disclosed
EP-1409452-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2004-04-21 EP disclosed
WO-2002098846-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147612-A1 Sulfonamide derivatives GRIN1, GRIN2A, GRIA1 GRIA4 9/4885GRIA2 7/4885PSEN1 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.